Simulect: redefining immunosuppressive strategies.
Moore
R
R
University Hospital of Wales Renal Unit, Cardiff, UK.
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D000077552:Basiliximab; D001706:Biopsy; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000191:economics / Q000379:methods*; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab